Free Trial

Alaunos Therapeutics (TCRT) Competitors

Alaunos Therapeutics logo
$3.19 -0.25 (-7.27%)
Closing price 04:00 PM Eastern
Extended Trading
$3.19 0.00 (0.00%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TCRT vs. CING, LSTA, AYTU, APLM, HOTH, EDSA, CLRB, SYBX, FNCH, and ASBP

Should you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Cingulate (CING), Lisata Therapeutics (LSTA), Aytu BioPharma (AYTU), Apollomics (APLM), Hoth Therapeutics (HOTH), Edesa Biotech (EDSA), Cellectar Biosciences (CLRB), Synlogic (SYBX), Finch Therapeutics Group (FNCH), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry.

Alaunos Therapeutics vs. Its Competitors

Cingulate (NASDAQ:CING) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

41.3% of Cingulate shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 4.0% of Cingulate shares are owned by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cingulate currently has a consensus price target of $27.75, indicating a potential upside of 593.75%. Given Cingulate's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cingulate is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cingulate
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics' return on equity of -168.02% beat Cingulate's return on equity.

Company Net Margins Return on Equity Return on Assets
CingulateN/A -232.16% -132.07%
Alaunos Therapeutics N/A -168.02%-121.37%

Alaunos Therapeutics has higher revenue and earnings than Cingulate. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CingulateN/AN/A-$15.55M-$4.10-0.98
Alaunos Therapeutics$6K1,172.86-$4.68M-$2.46-1.30

Cingulate has a beta of -0.75, suggesting that its share price is 175% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.84, suggesting that its share price is 184% less volatile than the S&P 500.

In the previous week, Cingulate had 9 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 11 mentions for Cingulate and 2 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.96 beat Cingulate's score of 0.12 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cingulate Neutral
Alaunos Therapeutics Positive

Summary

Cingulate and Alaunos Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRT vs. The Competition

MetricAlaunos TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.04M$2.62B$6.05B$10.51B
Dividend YieldN/A57.77%5.73%4.80%
P/E Ratio-1.3022.7985.3627.35
Price / Sales1,172.86557.62516.10196.40
Price / CashN/A174.0137.5761.53
Price / Book2.475.5112.426.82
Net Income-$4.68M$33.06M$3.32B$276.80M
7 Day Performance-13.78%0.96%0.97%0.26%
1 Month Performance41.78%14.26%10.70%8.29%
1 Year Performance44.34%0.86%76.19%35.59%

Alaunos Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
1.1983 of 5 stars
$3.19
-7.3%
N/A+65.4%$7.04M$6K-1.3040Analyst Forecast
Gap Down
CING
Cingulate
2.5421 of 5 stars
$4.15
+1.5%
$26.25
+532.5%
-8.0%$22.14MN/A-1.0120News Coverage
Analyst Forecast
LSTA
Lisata Therapeutics
2.5994 of 5 stars
$2.47
-1.6%
$23.50
+851.4%
-17.1%$21.98M$1M-1.1130Gap Down
AYTU
Aytu BioPharma
3.6393 of 5 stars
$2.36
+7.8%
$9.17
+288.4%
+5.3%$21.71M$66.38M-0.84160Analyst Forecast
Gap Up
High Trading Volume
APLM
Apollomics
0.7995 of 5 stars
$18.43
+51.3%
N/A+34.5%$20.34M$1.49M0.0045Trending News
Trading Halted
High Trading Volume
HOTH
Hoth Therapeutics
1.9306 of 5 stars
$1.53
flat
$4.00
+161.4%
+87.8%$20.29MN/A-1.434
EDSA
Edesa Biotech
3.1911 of 5 stars
$2.75
-4.5%
$5.00
+81.8%
-41.5%$20.27MN/A-2.0820News Coverage
CLRB
Cellectar Biosciences
2.1895 of 5 stars
$5.13
-16.9%
$375.00
+7,209.9%
-92.0%$19.69MN/A-0.2610High Trading Volume
SYBX
Synlogic
0.7098 of 5 stars
$1.70
+1.3%
N/A+22.1%$19.58M$10K-21.1980
FNCH
Finch Therapeutics Group
N/A$12.03
-0.8%
N/A+3.9%$19.32MN/A-1.36190
ASBP
Aspire Biopharma
N/A$0.36
-6.7%
N/AN/A$19.06MN/A0.00N/A

Related Companies and Tools


This page (NASDAQ:TCRT) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners